The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1427
Brimonidine Gel (Mirvaso) for Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the selective alpha2-adrenergic receptor agonist brimonidine as a 0.33% gel (Mirvaso – Galderma) for topical treatment of adults with persistent facial erythema of rosacea. Brimonidine is also available in ophthalmic formulations for treatment of glaucoma.1,2

MECHANISM OF ACTION — Taken systemically, selective alpha2 agonists lower blood pressure by decreasing sympathetic outflow from the brain. Applied to the eye, they decrease production of aqueous humor. Applied to the skin, they cause vasoconstriction and can reduce erythema.

TREATMENT OF ROSACEA — Rosacea is a common, chronic inflammatory facial eruption of unknown cause characterized by erythema, telangiectasia, and recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brimonidine Gel (Mirvaso) for Rosacea
Article code: 1427b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian